Compare Amylx Pharmaceuticals Inc (AMLX) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Dover Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B), while Dover Corp trades at $208.53 (market cap $28.07B). The key difference: Dover Corp is far larger — about 10.6× Amylx Pharmaceuticals Inc's market cap, and Dover Corp pays a 1.01% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DOV | |
|---|---|---|
Market Cap | $2.64B | $28.07B |
Sector | Health | Industrials |
52-Week High | $24.19 | $233.31 |
52-Week Low | $7.82 | $161.16 |
Enterprise Value | $2.39B | $29.58B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
DOV trades at $207.92, down 1.04% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, maintains a 13.48% net income margin, and recently raised its dividend. Analyst consensus is strongly bullish with a $232.33 price target. Recent news highlights manufacturing strength and strategic acquisitions like Cloeren, supporting growth in data center and AI segments.
The outlook is positive given earnings momentum, dividend growth, and raised 2026 guidance. Risks include market volatility and execution of acquisitions. With no sell ratings and solid cash flow, DOV offers a balanced opportunity for growth and income, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
